AlphaGen
Access AlphaGen
Company Narratives

Otsuka Pakistan FY2026: Margin Recovery Deepens Even as Sales Momentum Cools

Otsuka Pakistan rebuilt margins sharply in FY2026, lifting PAT to PKR 472m, but softer Q4 sales and working-capital absorption temper the headline recovery.

Sep 17, 2026

Verdict: Otsuka Pakistan’s FY2026 result is more than a rebound from a weak base: the company rebuilt gross margin while sales grew only moderately. Revenue rose 8.8% to PKR 4.11 billion, but cost of sales fell 9.1%, lifting gross profit 69% and gross margin to 35.5% from 22.8%. Operating profit rose to PKR 783 million and PAT to PKR 472 million. The quality is mixed, however. Management had already attributed much of the nine-month margin recovery to price adjustments and cost control, while a large foreign-exchange gain on the parent-company loan also boosted non-operating earnings. Operating cash flow actually fell 9.5% despite the profit surge because inventory, receivables and tax payments absorbed cash.

Results at a glance

Company Name: Otsuka Pakistan Limited

Ticker: OTSU

Reporting period: year ended June 30, 2026. The September 2 PSX filing says audited financial statements are enclosed and presents standalone company accounts in PKR thousands. The six-page result package does not include the independent auditor’s report, so no audit opinion is inferred from the package itself. The March 2026 nine-month statements used to derive Q4 are explicitly unaudited.

Alpha QoQ Score: 71.23

TTM Performance Score: 98.58

3Y Business Perf Score: 87.23

Sector Leadership Score: 54.2089

These four scores are AlphaGen model outputs, not company-reported figures.

What improved

The strongest improvement was at the gross-profit line. Cost of sales declined to PKR 2.652 billion even though revenue increased, taking full-year gross margin above not only FY2025’s 22.8% but also the PSX-standardized FY2024 and FY2023 margins of 18.2% and 21.2%. This matters because it shows the earnings recovery was not created solely below the operating line.

Management’s nine-month review provides the clearest causal explanation available before the annual report. Through March, it said sales were up 14% and gross margin had improved to 34% from 21%, driven by price adjustments and effective cost-control measures. That explanation is consistent with the full-year arithmetic: the Q4 gross margin remained around 39% even as Q4 sales were lower year on year. The result package does not provide a Q4-specific management bridge, so extending the nine-month explanation into Q4 is an inference rather than a company statement.

The company also generated a much stronger operating-profit margin. Selling and distribution expenses rose 28% and administrative expenses 13%, yet the gain in gross profit was large enough to absorb that cost growth. Through March, management said distribution costs had risen because of advertising and promotion for two new enteral-nutrition products, Neo-Mune and Once-Dialyze, a dedicated EN sales team and a door-to-door distributor warehouse logistics model. Those expenses are therefore not simply overhead inflation; part represents investment in diversification beyond the core IV-solutions franchise.

Another important boost came from foreign exchange, but it is lower-quality than the gross-margin improvement. The nine-month directors’ report said rupee appreciation produced a PKR 122 million net exchange gain on the foreign-currency loan from the parent company. The FY2026 cash-flow statement shows a PKR 140.8 million unrealized exchange gain on the related-party loan among non-cash adjustments. Other income more than doubled to PKR 291.7 million while other expenses fell to PKR 95.0 million. That helped reported earnings, but exchange remeasurement can reverse with currency movements and should not be treated as a stable operating driver.

What weakened / needs attention

Sales momentum weakened in the second half. Q3 revenue fell 12.5% year on year, and the derived Q4 revenue decline was about 3.7%. Management attributed the Q3 weakness to seasonality, closure of the Pakistan-Afghanistan border that halted exports, and the cessation of Afghan citizens travelling to Pakistan for treatment. Because nine-month revenue was still up 14% but full-year growth slowed to 8.8%, the final quarter did not restore the earlier top-line pace.

The Afghanistan issue matters, but it should be kept in proportion. Otsuka’s business is overwhelmingly domestic and its core activity remains manufacturing and distributing intravenous infusions, alongside pharmaceutical products, nutritional foods and medical equipment. Management nevertheless identified Afghanistan as a direct Q3 demand disruption. The next cycle will show whether cross-border sales normalize or whether growth increasingly depends on domestic pricing, product launches and clinical-nutrition expansion.

Cash conversion was the clearest financial weakness. Net cash generated from operating activities declined to PKR 329.8 million from PKR 364.5 million even though PAT increased by more than PKR 444 million. Before working-capital changes, operating cash flow was much stronger at PKR 841.9 million, but stock-in-trade absorbed PKR 245.5 million and trade debts absorbed PKR 93.7 million. Cash taxes paid also rose to PKR 233.5 million from PKR 95.2 million. In other words, the income-statement recovery was real, but not all of it converted into cash during the year.

The year-end balance sheet tells the same story. Inventory increased 25% to PKR 1.300 billion, and trade debts more than doubled to PKR 183.5 million. Trade and other payables also rose 16% to PKR 891.0 million. Liquidity nevertheless improved: current assets grew to PKR 2.291 billion against PKR 1.861 billion of current liabilities, taking the current ratio to about 1.23 from just below 1.0. The short-term related-party loan declined 13% to PKR 942.7 million. So the issue is not immediate balance-sheet stress; it is whether inventory and receivables can be converted efficiently as the business expands.

Finance cost nearly doubled to PKR 11.2 million, but its absolute size remains small relative to operating profit. More important is the continuing dependence on a foreign-currency related-party loan, because the same liability that generated a favorable exchange gain in FY2026 can create losses if the rupee moves the other way.

Recurring versus exceptional drivers

More recurring / operational: the gross-margin rebuild, price and cost discipline, domestic execution and the expansion into enteral nutrition. These can carry into future periods if volumes hold and the higher selling spend converts into revenue.

More volatile / non-recurring: the foreign-exchange benefit on the parent-company loan and year-specific credit-loss effects. A PKR 140.8 million unrealized exchange gain is economically meaningful against PKR 472 million of PAT, but it depends on currency movement rather than pharmaceutical demand. FY2025 also benefited from a PKR 50.0 million reversal of expected-credit-loss provisions on trade debts, which did not recur in FY2026.

The tax line also rose sharply to PKR 299.6 million from PKR 79.9 million as profit recovered. Derived Q4 taxation was about PKR 88.8 million against derived Q4 PBT of PKR 180.9 million, an unusually high quarterly effective rate. Without the year-end tax notes, which were not included in the six-page PSX result package, it would be inappropriate to infer a specific cause.

Sector and regulatory context

Otsuka’s growth came against a weak domestic production backdrop. Pakistan Bureau of Statistics reported that pharmaceutical large-scale-manufacturing output declined 8.87% in July-June FY2026, while overall LSM grew 4.98%. Otsuka’s 8.8% revenue increase and large margin expansion therefore should not be read simply as participation in a broad sector-volume boom. Company-specific pricing, cost control and mix were important.

Pricing regulation is also relevant but should not be over-applied. DRAP documents confirm that Pakistan deregulated prices of non-essential medicines in February 2024 and later commissioned a national survey to measure the effect. A Highnoon Laboratories interim report similarly described non-essential-drug price deregulation and macro stability as easing sector pressure. Otsuka itself specifically cited price adjustments as a margin driver through March 2026, but its filings do not quantify how much of its portfolio was covered by deregulation. The regulatory reform is therefore useful sector context, not proof of the size of Otsuka’s pricing benefit.

The broader pharmaceutical sector was also pushing exports: the Finance Division said in November 2025 that industry representatives reported 34% year-on-year pharmaceutical export growth. Otsuka did not fully participate in that tailwind during Q3 because its Afghanistan exports were halted by border disruption. This divergence reinforces why company-specific geography matters more than broad sector export headlines.

Historical pattern

FY2026 marks a major break from the previous two years. PSX data show Otsuka’s gross margin had fallen to 18.2% in FY2024 before recovering to 22.8% in FY2025; FY2026 reached 35.5%. PAT had been slightly negative in FY2024 and only PKR 27.7 million in FY2025 before reaching PKR 472.1 million. The improvement is therefore not simply year-on-year noise—it represents a restoration of operating economics after a weak period. The question now is whether the company can hold a mid-30s gross margin while rebuilding sales momentum.

What to monitor next

  • Sales growth after the Q3/Q4 slowdown, particularly whether domestic demand and clinical-nutrition products offset the disrupted Afghanistan channel.
  • Gross margin sustainability after the jump to 35.5%, especially the balance between further pricing, product mix and imported input costs.
  • Foreign-exchange sensitivity on the parent-company loan; FY2026’s gain should not be extrapolated mechanically.
  • Inventory and trade receivables, which consumed substantial cash and grew faster than sales.
  • Operating cash conversion: a stronger P&L should eventually translate into operating cash flow growth.
  • Enteral-nutrition execution, including whether the new sales team and promotional spend translate into enough revenue to justify the higher distribution cost.
  • Input-cost risk from LDPE and other imported materials; management flagged petroleum-linked LDPE and regional supply-chain disruptions as structural risks.
  • The annual report and full notes, once transmitted, for the detailed tax, related-party-loan, product/geographic sales and audit-opinion disclosures not contained in the abbreviated result package.

Bottom line

Otsuka Pakistan finished FY2026 with a much healthier operating model than it entered the year with. The most convincing evidence is not the 17-fold increase in PAT by itself, but the combination of lower cost of sales, a 12.6-point gross-margin expansion and a strong derived Q4 margin despite softer sales. At the same time, the profit jump contains a meaningful FX component, and cash conversion lagged because working capital expanded. FY2027 should therefore be judged on three tests: whether sales regain momentum, whether the mid-30s gross margin survives without relying on unusual currency gains, and whether the higher earnings begin converting into stronger operating cash flow.

Public source trail

Explore more research

All articles